198 related articles for article (PubMed ID: 21037081)
21. Differential effects of polymorphic alleles of FGF receptor 4 on colon cancer growth and metastasis.
Heinzle C; Gsur A; Hunjadi M; Erdem Z; Gauglhofer C; Stättner S; Karner J; Klimpfinger M; Wrba F; Reti A; Hegedus B; Baierl A; Grasl-Kraupp B; Holzmann K; Grusch M; Berger W; Marian B
Cancer Res; 2012 Nov; 72(22):5767-77. PubMed ID: 22971346
[TBL] [Abstract][Full Text] [Related]
22. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
da Costa Andrade VC; Parise O; Hors CP; de Melo Martins PC; Silva AP; Garicochea B
Exp Mol Pathol; 2007 Feb; 82(1):53-7. PubMed ID: 17084840
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.
Naidu R; Har YC; Taib NA
Oncol Res; 2009; 18(2-3):65-71. PubMed ID: 20066896
[TBL] [Abstract][Full Text] [Related]
24. Re-evaluating the FGFR4 (G388R) germline mutation in different cancers in Pakistani population.
Mansoor Q; Fayyaz S; Farooqi AA; Bhatti S; Ismail M
J Exp Ther Oncol; 2013; 10(3):215-7. PubMed ID: 24416997
[TBL] [Abstract][Full Text] [Related]
25. Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.
Liu J; Zhang X; Liu A; Zhang D; Su Y; Liu Y; You D; Yuan L; Kong X; Wang X; Sun P
Oncotarget; 2016 Jun; 7(24):36755-36766. PubMed ID: 27191984
[TBL] [Abstract][Full Text] [Related]
26. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression.
Kittiniyom K; Gorse KM; Dalbegue F; Lichy JH; Taubenberger JK; Newsham IF
Breast Cancer Res; 2001; 3(3):192-8. PubMed ID: 11305954
[TBL] [Abstract][Full Text] [Related]
27. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
Ezzat S; Zheng L; Winer D; Asa SL
Mol Endocrinol; 2006 Nov; 20(11):2965-75. PubMed ID: 16857743
[TBL] [Abstract][Full Text] [Related]
28. Loss of heterozygosity in bilateral breast cancer.
Kollias J; Man S; Marafie M; Carpenter K; Pinder S; Ellis IO; Blamey RW; Cross G; Brook JD
Breast Cancer Res Treat; 2000 Dec; 64(3):241-51. PubMed ID: 11200774
[TBL] [Abstract][Full Text] [Related]
29. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
30. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
Falvella FS; Frullanti E; Galvan A; Spinola M; Noci S; De Cecco L; Nosotti M; Santambrogio L; Incarbone M; Alloisio M; Calabrò E; Pastorino U; Skaug V; Haugen A; Taioli E; Dragani TA
Int J Cancer; 2009 Jun; 124(12):2880-5. PubMed ID: 19296538
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity analysis in ductal lavage samples from BRCA1 and BRCA2 carriers: a cautionary tale.
Antill YC; Mitchell G; Johnson SA; Devereux L; Milner A; Phillips KA; Campbell IG
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1396-8. PubMed ID: 16835342
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity on chromosome 11p15 during histological progression in microdissected ductal carcinoma of the breast.
Lichy JH; Zavar M; Tsai MM; O'Leary TJ; Taubenberger JK
Am J Pathol; 1998 Jul; 153(1):271-8. PubMed ID: 9665488
[TBL] [Abstract][Full Text] [Related]
34. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
[TBL] [Abstract][Full Text] [Related]
35. Coordination of TP53 abnormalities in breast cancer: data from analysis of TP53 polymorphisms, loss of heterozygosity, methylation, and mutations.
Denisov EV; Sukhanovskaya TV; Dultseva TS; Malinovskaya EA; Litviakov NV; Slonimskaya EM; Choinzonov EL; Cherdyntseva NV
Genet Test Mol Biomarkers; 2011 Dec; 15(12):901-7. PubMed ID: 21810023
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
Sarrió D; Moreno-Bueno G; Hardisson D; Sánchez-Estévez C; Guo M; Herman JG; Gamallo C; Esteller M; Palacios J
Int J Cancer; 2003 Aug; 106(2):208-15. PubMed ID: 12800196
[TBL] [Abstract][Full Text] [Related]
37. Biallelic inactivation of retinoic acid receptor beta2 gene by epigenetic change in breast cancer.
Yang Q; Mori I; Shan L; Nakamura M; Nakamura Y; Utsunomiya H; Yoshimura G; Suzuma T; Tamaki T; Umemura T; Sakurai T; Kakudo K
Am J Pathol; 2001 Jan; 158(1):299-303. PubMed ID: 11141504
[TBL] [Abstract][Full Text] [Related]
38. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
[TBL] [Abstract][Full Text] [Related]
39. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
40. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
